ORCHESTRA BIOMED HOLDINGS IN (OBIO) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:OBIO • US68572M1062

3.92 USD
+0.01 (+0.26%)
Last: Feb 9, 2026, 08:22 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

OBIO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 186 industry peers in the Health Care Equipment & Supplies industry. The financial health of OBIO is average, but there are quite some concerns on its profitability. OBIO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year OBIO has reported negative net income.
  • OBIO had a negative operating cash flow in the past year.
  • OBIO had negative earnings in each of the past 5 years.
  • In the past 5 years OBIO always reported negative operating cash flow.
OBIO Yearly Net Income VS EBIT VS OCF VS FCFOBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • OBIO has a worse Return On Assets (-71.66%) than 73.12% of its industry peers.
  • OBIO has a Return On Equity of -171.70%. This is in the lower half of the industry: OBIO underperforms 69.35% of its industry peers.
Industry RankSector Rank
ROA -71.66%
ROE -171.7%
ROIC N/A
ROA(3y)-56.32%
ROA(5y)-79.02%
ROE(3y)-108.38%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OBIO Yearly ROA, ROE, ROICOBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

  • The Gross Margin of OBIO (93.01%) is better than 98.92% of its industry peers.
  • OBIO's Gross Margin has declined in the last couple of years.
  • OBIO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 93.01%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.78%
GM growth 5YN/A
OBIO Yearly Profit, Operating, Gross MarginsOBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 1K -1K 2K -2K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • OBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • OBIO has more shares outstanding than it did 1 year ago.
  • Compared to 1 year ago, OBIO has a worse debt to assets ratio.
OBIO Yearly Shares OutstandingOBIO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M
OBIO Yearly Total Debt VS Total AssetsOBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • Based on the Altman-Z score of -4.22, we must say that OBIO is in the distress zone and has some risk of bankruptcy.
  • OBIO has a Altman-Z score of -4.22. This is in the lower half of the industry: OBIO underperforms 65.59% of its industry peers.
  • OBIO has a Debt/Equity ratio of 0.32. This is a healthy value indicating a solid balance between debt and equity.
  • OBIO has a Debt to Equity ratio (0.32) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.32
Debt/FCF N/A
Altman-Z -4.22
ROIC/WACCN/A
WACC9.74%
OBIO Yearly LT Debt VS Equity VS FCFOBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

  • A Current Ratio of 4.73 indicates that OBIO has no problem at all paying its short term obligations.
  • OBIO's Current ratio of 4.73 is fine compared to the rest of the industry. OBIO outperforms 75.81% of its industry peers.
  • OBIO has a Quick Ratio of 4.72. This indicates that OBIO is financially healthy and has no problem in meeting its short term obligations.
  • OBIO has a Quick ratio of 4.72. This is amongst the best in the industry. OBIO outperforms 81.72% of its industry peers.
Industry RankSector Rank
Current Ratio 4.73
Quick Ratio 4.72
OBIO Yearly Current Assets VS Current LiabilitesOBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • OBIO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -12.42%.
  • OBIO shows a small growth in Revenue. In the last year, the Revenue has grown by 6.46%.
EPS 1Y (TTM)-12.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.44%
Revenue 1Y (TTM)6.46%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-12.77%

3.2 Future

  • Based on estimates for the next years, OBIO will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.50% on average per year.
  • Based on estimates for the next years, OBIO will show a very strong growth in Revenue. The Revenue will grow by 74.50% on average per year.
EPS Next Y-7.43%
EPS Next 2Y0.96%
EPS Next 3Y6.84%
EPS Next 5Y13.5%
Revenue Next Year6.59%
Revenue Next 2Y4.43%
Revenue Next 3Y-6%
Revenue Next 5Y74.5%

3.3 Evolution

OBIO Yearly Revenue VS EstimatesOBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 50M 100M 150M 200M 250M
OBIO Yearly EPS VS EstimatesOBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -2 -4 -6 -8

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for OBIO. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OBIO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OBIO Price Earnings VS Forward Price EarningsOBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OBIO Per share dataOBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.96%
EPS Next 3Y6.84%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for OBIO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ORCHESTRA BIOMED HOLDINGS IN

NASDAQ:OBIO (2/9/2026, 8:22:37 PM)

3.92

+0.01 (+0.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-10
Earnings (Next)N/A
Inst Owners29.32%
Inst Owner Change0.58%
Ins Owners2.95%
Ins Owner Change-4.06%
Market Cap221.32M
Revenue(TTM)2.82M
Net Income(TTM)-75.10M
Analysts81.43
Price Target13.7 (249.49%)
Short Float %1.99%
Short Ratio3.3
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.25%
Min EPS beat(2)2.68%
Max EPS beat(2)9.82%
EPS beat(4)4
Avg EPS beat(4)4.05%
Min EPS beat(4)0.13%
Max EPS beat(4)9.82%
EPS beat(8)7
Avg EPS beat(8)2.55%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)14.62%
Min Revenue beat(2)11.42%
Max Revenue beat(2)17.83%
Revenue beat(4)3
Avg Revenue beat(4)5.09%
Min Revenue beat(4)-70.51%
Max Revenue beat(4)61.63%
Revenue beat(8)4
Avg Revenue beat(8)-7.94%
Revenue beat(12)6
Avg Revenue beat(12)-2.62%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.05%
PT rev (3m)-0.53%
EPS NQ rev (1m)0.33%
EPS NQ rev (3m)7.7%
EPS NY rev (1m)0.21%
EPS NY rev (3m)1.14%
Revenue NQ rev (1m)5.22%
Revenue NQ rev (3m)5.25%
Revenue NY rev (1m)0.67%
Revenue NY rev (3m)3.98%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 78.54
P/FCF N/A
P/OCF N/A
P/B 5.06
P/tB 5.06
EV/EBITDA N/A
EPS(TTM)-1.81
EYN/A
EPS(NY)-1.63
Fwd EYN/A
FCF(TTM)-1.09
FCFYN/A
OCF(TTM)-1.07
OCFYN/A
SpS0.05
BVpS0.77
TBVpS0.77
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -71.66%
ROE -171.7%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 93.01%
FCFM N/A
ROA(3y)-56.32%
ROA(5y)-79.02%
ROE(3y)-108.38%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.78%
GM growth 5YN/A
F-Score4
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.32
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 353.8%
Cap/Sales 41.31%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.73
Quick Ratio 4.72
Altman-Z -4.22
F-Score4
WACC9.74%
ROIC/WACCN/A
Cap/Depr(3y)194.88%
Cap/Depr(5y)224.07%
Cap/Sales(3y)17.77%
Cap/Sales(5y)19.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.44%
EPS Next Y-7.43%
EPS Next 2Y0.96%
EPS Next 3Y6.84%
EPS Next 5Y13.5%
Revenue 1Y (TTM)6.46%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-12.77%
Revenue Next Year6.59%
Revenue Next 2Y4.43%
Revenue Next 3Y-6%
Revenue Next 5Y74.5%
EBIT growth 1Y-25.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-15.49%
EBIT Next 3Y-4.45%
EBIT Next 5Y4.75%
FCF growth 1Y-39.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-37.23%
OCF growth 3YN/A
OCF growth 5YN/A

ORCHESTRA BIOMED HOLDINGS IN / OBIO FAQ

Can you provide the ChartMill fundamental rating for ORCHESTRA BIOMED HOLDINGS IN?

ChartMill assigns a fundamental rating of 2 / 10 to OBIO.


Can you provide the valuation status for ORCHESTRA BIOMED HOLDINGS IN?

ChartMill assigns a valuation rating of 0 / 10 to ORCHESTRA BIOMED HOLDINGS IN (OBIO). This can be considered as Overvalued.


Can you provide the profitability details for ORCHESTRA BIOMED HOLDINGS IN?

ORCHESTRA BIOMED HOLDINGS IN (OBIO) has a profitability rating of 1 / 10.


Can you provide the financial health for OBIO stock?

The financial health rating of ORCHESTRA BIOMED HOLDINGS IN (OBIO) is 4 / 10.